Commercial Services and Supplies
Company Overview of Juvenile Diabetes Research Foundation International Inc.
Juvenile Diabetes Research Foundation International Inc. (JDRF) is a not-for-profit organization that focuses on juvenile diabetes cure research and development services. The organization offers grants for diabetes clinical trials to laboratories, educational institutions, and pharmaceutical and medical research companies. JDRF was founded in 1970 and is headquartered in New York City with an additional office in Houston, Texas.
120 Wall Street
New York, NY 10005-4001
Founded in 1970
Key Executives for Juvenile Diabetes Research Foundation International Inc.
Chief Executive Officer, President and Director
Executive Vice President for Development and Chief Operating Officer
Vice President-Customer Services
President of Long Island Chapter
Compensation as of Fiscal Year 2014.
Juvenile Diabetes Research Foundation International Inc. Key Developments
Selecta Biosciences, Inc., JDRF and Sanofi Extends Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes
Mar 27 15
Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selectas proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells. JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies.
JDRF Supports Janssen's Disease Interception Approach to Prevent the Clinical Onset of Type 1 Diabetes
Feb 12 15
JDRF announced its alignment with an innovative scientific approach of Janssen Research & Development, LLC and the company's Disease Interception Accelerator (DIA) group, which will focus on transforming type 1 diabetes through its disease interception strategy. JDRF will work with Janssen scientists to further identify the root cause(s) of T1D with the aim of intercepting and eliminating the disease before clinical symptoms emerge, effectively seeking to create a new paradigm in health care for T1D.
JDRF Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:30 AM
Feb 6 15
JDRF Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:30 AM. Venue: The Waldorf Astoria, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries